1. Scrip
  2. >>Therapy Areas

Earlier R&D Programs, Maturing Candidates Emerge From Bristol’s Pipeline

Mid-Stage Milvexian Cleared First Proof-Of-Concept Hurdle

 
• By Mandy Jackson

BMS is advancing a growing Phase I and II R&D pipeline, including a Factor XIa inhibitor with lower bleeding risk than current anticoagulants, as well as other internal and external research programs.

Pharmaceutical research developing genetic medicine
BMS has 64 assets in Phase I and II development • Source: Alamy

Bristol Myers Squibb Company is under pressure to bring new drugs to market before several of its current blockbuster products face generic and biosimilar competition. But in addition to a suite of late-stage and newly approved therapies that it believes will generate more than $25bn in new revenue by 2029, the company has a rapidly growing pipeline of Phase I and II research and development programs with many drug candidates on the cusp of proof-of-concept data or nearing advancement into Phase III.

Bristol showcased some of its early and mid-stage clinical programs that may help BMS grow its revenue base later in this decade and beyond during an investor event on 16...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.